stockrowGenmab A/S Sponsored ADR
GMAB Healthcare Biotechnology
Genmab A/S Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 19.2% from fiscal 2024.
- Revenue
- +24.9%
- EPS
- −9.26%
- Free cash flow
- −7.69%
Quarter to June 2026, against a year earlier
Follow GMAB
Alert me
Genmab A/S Sponsored ADR (GMAB) Revenue growth
Genmab A/S Sponsored ADR's revenue growth over the twelve months to 30 June 2026 was 22.3%, up 3.1 percentage points from fiscal 2025 (19.2%). Over the past ten years it has ranged from −32.4% (fiscal 2016) to 92.6% (fiscal 2020); the current reading is higher than 40% of that period. That is above the Biotechnology industry median of 6.26% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 19.2% | (11.29) |
| FY2024 | 30.5% | 14.74 |
| FY2023 | 15.7% | (37.40) |
| FY2022 | 53.1% | 66.02 |
| FY2021 | −12.9% | (105.46) |
| FY2020 | 92.6% | 24.72 |
| FY2019 | 67.9% | 42.04 |
| FY2018 | 25.8% | (22.03) |
| FY2017 | 47.9% | 80.21 |
| FY2016 | −32.4% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Jun 2026 | 24.9% | (0.45) |
| Mar 2026 | 25.3% | 10.68 |
| Dec 2025 | 14.6% | (10.62) |
| Sep 2025 | 25.3% | 6.51 |
| 27 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| RVMD Revolution Medicines, Inc. compare | 491.1% |
| INSM Insmed, Inc. compare | 240.0% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 56.2% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 32.9% |
| INCY Incyte Corporation compare | 24.9% |
| GMAB Genmab A/S Sponsored ADR | 22.3% |
| RPRX Royalty Pharma PLC compare | 11.4% |
| BNTX BioNTech SE Sponsored ADR compare | −22.7% |
| ROIV Roivant Sciences Ltd. compare | −67.6% |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on GMAB
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement